BTIG Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Cullinan Therapeutics (CGEM) Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today received Human Research Ethics Committee (HREC) approval in Australia to initiate its global Phase 1 clinical trial to evaluate CLN-978, its CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).

SLE affects approximately 430,000 individuals... More

TD Cowen Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

TD Cowen analyst Marc Frahm reiterated a Buy rating on Cullinan Oncology Inc. (NASDAQ: CGEM).

The analyst commented, "At ESMO, CGEM presented updated data from Module C of the REZILIENT-1 Ph IIb trial of zipalertinib (EGFR exon20ins TKI) in post-ami... More

H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

H.C. Wainwright analyst Edward White reiterated a Buy rating and $28.00 price target on Cullinan Oncology Inc. (NASDAQ: CGEM).

The analyst commented: "On September 14, 2024, positive updated data from Module C of the companys pivotal Phase 2b REZILIENT1 clinical trial were presented at the European Society for Medical Oncology (ESMO) Congress 2024. Zipalertinib is an oral small molecule irreversible epidermal growth factor (EGFR) inhibitor. It has breakthrough therapy designation from the FDA for the... More

Cullinan Therapeutics (CGEM) Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today shared that it has submitted an Investigational New Drug (IND) application to the... More